Gan & Lee Pharmaceuticals has been granted orphan drug designation for GLR2007 from the European Medicine Agency (EMA) for the treatment of glioma, a type of tumor found in the brain and spinal cord. The Chinese biopharma company is currently studying GLR2007 in a phase 1 clinical trial for the treatment of advanced solid tumors. […]
Gan & Lee Pharmaceuticals has been given orphan drug designation from the US Food and Drug Administration (FDA) for GLR2007 for the treatment of malignant glioma, an aggressive primary brain tumor. According to the Chinese biopharma company, GLR2007 is an inhibitor of cyclin-dependent kinase 4/6 (CDK 4/6), which is being developed for the treatment of […]